Concepedia

Mark J. Levis

MJ

196

Publications

20.5K

Citations

73

H-Index

1992

Active since

Affiliations

Johns Hopkins University(Current)

Sidney Kimmel Comprehensive Cancer Center

University of Pennsylvania

The University of Texas MD Anderson Cancer Center

Johns Hopkins Medicine

Mark J. Levis is an author at Johns Hopkins University specializing in medicine, oncology, and hematology.

ORCID

Top concepts

Publications per year

1992–2025

196

Publications

196

Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML

Alexander E. Perl, Giovanni Martinelli, Jörge E. Cortes et al. · New England Journal of Medicine · 2019 · 1.2K citations · Full text

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

Catherine C. Smith, Qi Wang, Chen-Shan Chin et al. · Nature · 2012 · 734 citations

, , +10

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

Patrick P. Zarrinkar, Ruwanthi N. Gunawardane, Merryl Cramer et al. · Blood · 2009 · 630 citations · Full text

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

B. Douglas Smith, Mark J. Levis, Miloslav Beran et al. · Blood · 2004 · 622 citations

Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML

Zhihong Zeng, Yue Shi, Ismael Samudio et al. · Blood · 2008 · 509 citations · Full text

Rows per page

1–5 of 196